Working... Menu

Open Label Safety Study of a Birch Pollen Allergen Extract

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00818181
Recruitment Status : Completed
First Posted : January 7, 2009
Last Update Posted : March 11, 2013
Information provided by (Responsible Party):
Allergopharma GmbH & Co. KG

Brief Summary:
This trial is performed to assess safety of a sublingual birch pollen extract.

Condition or disease Intervention/treatment Phase
Rhinoconjunctivitis Drug: Biological: AL0206st Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre Open Label Safety Study of a Sublingual Specific Immunotherapy With a Solution of Birch Pollen Allergen Extract in Patients With Clinically Relevant Birch Pollen Allergy
Study Start Date : June 2008
Actual Primary Completion Date : February 2009
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Bee pollen

Arm Intervention/treatment
Experimental: Solution of birch pollen allergen extract
In total up to 4 drops (dose for maintainace therapy)are administered under the tongue.
Drug: Biological: AL0206st

Primary Outcome Measures :
  1. number of patients with at least one adverse event [ Time Frame: 8 months ]
    Between Visit 03 and Visit 05 (June 2008 - January 2009)

Secondary Outcome Measures :
  1. Systemic reactions [ Time Frame: Entire treatment period ]
    The occurrence of systemic reactions during the entire treatment period: For this purpose patients completed a diary covering the treatment phase.

Other Outcome Measures:
  1. Immunologic parameters [ Time Frame: during the course of the study ]
    Immunologic parameters (IgE, IgG1 and IgG4) were evaluated during the course of the study in order to obtain evidence of the immunologic effects.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Allergic rhinoconjunctivitis attributable to birch pollen
  • Positive SPT
  • Positive EAST

Exclusion Criteria:

  • Serious chronic diseases
  • Other perennial allergies
  • Partly controlled asthma

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00818181

Layout table for location information
Prof. Dr. Nicolas Hunzelmann
Cologne, Germany, 50931
Sponsors and Collaborators
Allergopharma GmbH & Co. KG
Layout table for investigator information
Principal Investigator: Nicolas Hunzelmann, Prof. Dr. University of Cologne

Additional Information:
Layout table for additonal information
Responsible Party: Allergopharma GmbH & Co. KG Identifier: NCT00818181     History of Changes
Other Study ID Numbers: AL0206st
2007-006053-24 ( EudraCT Number )
First Posted: January 7, 2009    Key Record Dates
Last Update Posted: March 11, 2013
Last Verified: March 2013

Keywords provided by Allergopharma GmbH & Co. KG:
Type I - Allergy, rhinoconjunctivitis

Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctival Diseases
Eye Diseases